Obesity
📧 Sign up to get email alerts when something new happens for Obesity.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-28EMA Authorised: Mounjaro (tirzepatide) — Eli Lilly Nederland B.V.
The EMA authorizes Mounjaro (tirzepatide) for therapeutic use in type 2 diabetes, obesity, and overweight conditions.
-
EMA approval · 2026-08-26EMA Authorised: Wegovy (semaglutide) — Novo Nordisk A/S
EMA authorises Wegovy (semaglutide) by Novo Nordisk A/S for obesity and overweight.
-
EMA approval · 2026-08-25EMA Authorised: Ablymico (liraglutide) — STADA Arzneimittel AG
Ablymico (liraglutide) has been authorised by EMA for obesity and overweight indications.
-
EMA approval · 2026-08-18EMA Authorised: Mounjaro (tirzepatide) — Eli Lilly Nederland B.V.
EMA authorised Mounjaro (tirzepatide) for therapeutic use in type 2 diabetes mellitus, obesity, and overweight conditions.
-
EMA approval · 2026-04-10EMA Authorised: Mysimba (bupropion hydrochloride;naltrexone hydrochloride) — Orexigen Therapeutics Ireland Limited
The EMA authorised Mysimba, a fixed-dose combination of bupropion hydrochloride and naltrexone hydrochloride, for obesity and overweight. Or…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-03-30EMA Authorised: Wegovy (semaglutide) — Novo Nordisk A/S
The European Medicines Agency authorised Wegovy (semaglutide) from Novo Nordisk A/S for obesity and overweight.
-
FDA approval · 2026-03-27FDA Approved: ALLI — Supplemental Application (Haleon US Holdings LLC)
The FDA approved a supplemental application for ALLI (orlistat) submitted by Haleon US Holdings LLC.
-
FDA approval · 2026-03-19FDA Approved: WEGOVY — Supplemental Application (Novo Nordisk)
FDA approved a supplemental application for Wegovy (semaglutide) from Novo Nordisk.
-
FDA approval · 2026-03-19FDA Approved: WEGOVY — Supplemental Application (Novo Nordisk)
The FDA approved a supplemental application for Wegovy (semaglutide) from Novo Nordisk, resulting in updated labeling.
-
FDA approval · 2026-03-06FDA Approved: PHENTERMINE AND TOPIRAMATE — Supplemental Application (Prasco Laboratories)
The FDA approved a supplemental NDA for a generic version of phentermine and topiramate by Prasco Laboratories, authorizing its use for weig…
-
EMA approval · 2026-02-26EMA Authorised: Mounjaro (tirzepatide) — Eli Lilly Nederland B.V.
The EMA authorised Mounjaro (tirzepatide) for adults with type 2 diabetes and for obesity/overweight, granting EU marketing authorisation to…
-
FDA approval · 2026-02-25FDA Approved: SAXENDA — Supplemental Application (Novo Nordisk)
FDA approved a supplemental application for SAXENDA (liraglutide) submitted by Novo Nordisk.
-
FDA approval · 2026-02-25FDA Approved: WEGOVY — Supplemental Application (Novo Nordisk)
The FDA approved Novo Nordisk's supplemental application for Wegovy (semaglutide), updating the approval to support its chronic weight-manag…
-
FDA approval · 2026-02-25FDA Approved: WEGOVY — Supplemental Application (Novo Nordisk)
FDA approved a supplemental application for Wegovy (semaglutide) from Novo Nordisk. The approval pertains to changes to the product labeling…
-
FDA approval · 2026-02-24FDA Approved: LIRAGLUTIDE — Original Application (Biocon Pharma Inc.)
The FDA approved Biocon Pharma Inc.'s liraglutide original application (ANDA 217063), providing a generic version of liraglutide.
-
FDA approval · 2026-02-24FDA Approved: LIRAGLUTIDE — Original Application (Orbicular Pharmaceutical Technologies Private Limited)
FDA approved the original application for a generic liraglutide product from Orbicular Pharmaceutical Technologies Private Limited.
-
FDA approval · 2026-01-29FDA Approved: WEGOVY — Supplemental Application (Novo Nordisk)
The FDA approved a supplemental application for Wegovy (semaglutide) from Novo Nordisk, providing regulatory approval for an expanded or upd…
-
FDA approval · 2026-01-29FDA Approved: WEGOVY — Supplemental Application (Novo Nordisk)
FDA approved a supplemental application for Wegovy (semaglutide) from Novo Nordisk. The snippet does not specify the exact new indication or…
-
FDA approval · 2026-01-20FDA Approved: ZEPBOUND — Supplemental Application (Eli Lilly and Company)
FDA approved a supplemental application for ZEPBOUND (tirzepatide) submitted by Eli Lilly and Company.
-
FDA approval · 2026-01-14FDA Approved: LIRAGLUTIDE — Original Application (Orbicular Pharmaceutical Technologies Private Limited)
FDA approves the original application for a generic liraglutide product from Orbicular Pharmaceutical Technologies Private Limited.
-
FDA approval · 2026-01-07FDA Approved: ZEPBOUND — Supplemental Application (Eli Lilly and Company)
FDA approved a supplemental application for ZEPBOUND (tirzepatide) by Eli Lilly and Company.
-
FDA approval · 2025-12-22FDA Approved: WEGOVY — Original Application (Novo Nordisk)
This FDA entry covers Novo Nordisk's original application for Wegovy (semaglutide). Wegovy is a GLP-1 receptor agonist approved for chronic …
-
FDA approval · 2025-11-21FDA Approved: WEGOVY — Supplemental Application (Novo Nordisk)
The FDA approved a supplemental application for Wegovy (semaglutide) from Novo Nordisk.
-
FDA approval · 2025-11-05FDA Approved: CONTRAVE EXTENDED-RELEASE — Supplemental Application (Nalpropion Pharmaceuticals LLC)
FDA approved a supplemental application for CONTRAVE EXTENDED-RELEASE (naltrexone hydrochloride and bupropion hydrochloride) by Nalpropion P…
-
FDA approval · 2025-10-15FDA Approved: LIRAGLUTIDE — Supplemental Application (Meitheal Pharmaceuticals Inc.)
FDA approved a supplemental application for liraglutide from Meitheal Pharmaceuticals Inc.